ClinicalTrials.gg
CompletedNCT07419672Updated Feb 19, 2026

Intra Oral Application (IOA) Testing Study of a Stannous Toothpaste

An interventional study of Negative Control Treatment Slurry (Fluoride-Free) and Active Comparator Fluoride Treatment (0.454% SnF) in Dental Caries, sponsored by Church & Dwight Company, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Church & Dwight Company, Inc. · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Aug 2024, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 193 studies in Dental Caries with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Dental Caries · United States.

Enrollment
125th of 168
31 · median 60
Started
2024
with 9 others
No phase
110 of 193
13 open now
Registered
187th of 193
by date

Among the 193 studies in Dental Caries with a site in United States, this one is the 125th largest by enrollment of the 168 interventional ones that give a count, is one of 10 that started in 2024, is one of 110 with no phase, and was the 187th registered.

Dental Caries

1,174 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

16 of the 193 studies in Dental Caries with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Dental Caries with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this crossover in-situ study is to determine the fluoride bioavailability and enamel remineralization potential of an experimental, placebo, and a positive control reference toothpaste.

Read the detailed description

Each 9-day test period was preceded by a washout period of at least four days during which subjects used a fluoride-free toothpaste. The washout phase ensured removal of residual fluoride exposure prior to beginning the next assigned dentifrice treatment. Subjects remained in good oral health and compliance was verified at the start of each test period.

03

Conditions studied

  • Dental Caries

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be 18 years of age or older,
  • have the ability to understand the information contained in the without the need for cognitive or language interpretation from any other person or source,
  • read and sign the Informed Consent and other necessary paperwork prior to initiation of study procedures,
  • be in good general and oral health based on medical/dental history,
  • have an existing useable dental appliance on file with the clinic or be willing to have one (1) or more dental impressions taken so that a dental appliance can be made to wear during the study,
  • have a sufficient functional maxillary dentition to support the palatal appliance, and overall the full (maxillary and mandibular) dentition must provide for proper mastication of food, no less than 16 teeth,
  • must be able to expectorate ≥ 1.5 ml of non-stimulated saliva over a 5-minute period*,
  • be willing to refrain from using non-study mouthwash, dentifrice, gum, mints, and other non-study oral care products during the entire length of the study (exception: xylitol free gum and mints will be allowed during acclimation/ only),
  • be willing to participate in the study, be able to follow the study directions, and be willing to return for all specified visits at their appointed time,
  • be willing to refrain from actively participating in another oral care, drug or medical device research study (participation in a marketing/opinion/behavioral study may be allowed so long as the Principal Investigator has provided permission to do so),
  • be willing and able to refrain from wearing a nightguard during testing periods (for nightguard wearers only), and
  • be willing to postpone all elective dental procedures, at the discretion of the Investigator/Designee, until the study has been completed.

    • Subjects who are unable to provide an adequate amount of saliva during the screening visit may be granted the opportunity to return to the dental clinic to try again (one time only) after adequate hydration.

Exclusion criteria

Exclusion Criteria:

  • advanced periodontal disease as characterized by purulent exudate, generalized mobility, etc., or undergoing active treatment for periodontitis,
  • pathologic lesions of the oral cavity (suspicious or confirmed; per Investigator/Designee discretion),
  • a medical condition that could be expected to interfere with the subject's safety during the study period, such as a true allergy to oral care product ingredients, including (but not limited to) artificial sweeteners, mint (peppermint, spearmint, etc.) or other artificial colors or flavorings, sodium fluoride, ingredients that are derived from seaweed or corn, etc.,
  • full dentures, orthodontic appliances (with the exception of a lower, fixed retainer), or other oral devices/appliances or dental work which, at the discretion of the Investigator/Designee, would interfere with the fit of the dental appliance,
  • self-reported pregnancy, plans to become pregnant, or is currently breastfeeding,
  • allergy/adverse reaction to dental impression materials including Silicon Dioxide, Calcium Sulfate, Magnesium Oxide or Tetrasodium Pyrophosphate,
  • any decayed, untreated dental sites (cavities) (per Investigator/Designee discretion),
  • having taken antibiotic or immune-suppressive drugs within the past 30 days or anticipating the need to take antibiotic or immune-suppressive drugs during the course of the study (per Investigator/Designee discretion),
  • a medical history disclosing a medical condition that has been known to cause individuals to become severely immuno-compromised, or
  • a medical history reporting that the subject has a current systemic or disease, such as diabetes, lupus, etc. (per Investigator/Designee discretion).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Placebo comparator
    Negative Control Toothpaste

    Participants will wear an intra-oral appliance (IOA) containing enamel specimens and brush and rinse twice daily with a negative-control toothpaste and slurry that contains no active fluoride. This arm provides a baseline reference for evaluating enamel fluoride uptake and remineralization responses relative to the test and comparator treatments.

    Drug: Negative Control Treatment Slurry (Fluoride-Free)

  • Active comparator
    Comparator

    Participants will wear an intra-oral appliance (IOA) containing enamel specimens and brush and rinse twice daily with a commercially available fluoride toothpaste and slurry of known efficacy in promoting enamel fluoride uptake and surface remineralization. This arm serves as an established reference standard for evaluating the performance of the test formulation.

    Drug: Active Comparator Fluoride Treatment (0.454% SnF)

  • Experimental
    Test Toothpaste

    Participants will wear an intra-oral appliance (IOA) containing enamel specimens and brush and rinse twice daily with the investigational fluoride toothpaste and slurry. This arm evaluates the ability of the test formulation to promote enamel fluoride uptake and remineralization relative to both the negative control and active comparator treatments.

    Drug: Test Fluoride Treatment (0.454% SnF) (Investigational Toothpaste)

Interventions

  • DrugNegative Control Treatment Slurry (Fluoride-Free)

    Fluoride-free toothpaste used with an intra-oral appliance (IOA) containing enamel specimens. Toothbrushing and rinsing with slurry twice daily for 2 minutes per administration while wearing the IOA, followed by expectoration without rinsing. Used to provide a baseline reference for enamel fluoride uptake and remineralization outcomes in an IOA model.

  • DrugActive Comparator Fluoride Treatment (0.454% SnF)

    Commercially available stannous fluoride toothpaste Toothbrushing and rinsing with slurry twice daily for 2 minutes per administration while wearing the IOA containing enamel specimens, followed by expectoration without rinsing. Serves as an established reference for promoting enamel fluoride uptake and surface remineralization in an IOA model.

  • DrugTest Fluoride Treatment (0.454% SnF) (Investigational Toothpaste)

    Investigational stannous fluoride toothpaste Toothbrushing and rinsing with slurry twice daily for 2 minutes per administration while wearing the IOA containing enamel specimens, followed by expectoration without rinsing. Intended to evaluate enamel fluoride uptake and remineralization performance versus negative control and active comparator treatments in an IOA model.

06

What researchers measure

Primary outcomes

  1. Percent Surface Microhardness Recovery (%SMHR)

    Time frame: End of each 9-day test period (three test periods in total)

  2. Post-treatment fluoride concentration (µg F/g enamel)

    Time frame: End of each 9-day test period (three test periods in total)

07

Study locations

1 site
  • Therametric Technologies, Inc.
    Noblesville, Indiana 46060, United States
08

References and documents

Individual participant data

Plan to share: No — The sponsor does not plan to share individual participant data (IPD) from this study. Summary results will be provided as required, but no de-identified datasets or additional supporting documents will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Nov 2024, 3 months.

Of 33 industry-sponsored interventional studies with no phase under Dental Caries, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 3 months is below that.

Counting every sponsor, half of 502 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 19, 2026
StartActual
Aug 12, 2024
Primary completionActual
Nov 21, 2024
CompletionActual
Nov 21, 2024
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07419672
Collaborators
Therametrics
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Aug 12, 2024
Primary completion
Nov 21, 2024
Completion
Nov 21, 2024
Last update
Feb 19, 2026

Study contacts

Annahita Ghassemi, PhD
study director · Church & Dwight, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion